Christopher Corless

Gastroenterology · 2002–2017

A researcher in the Science corpus: 19 papers; trusts 7 researchers and is trusted by 2 researchers here, as inferred from the citation graph.

Subfields

• Gastroenterology — 103 citations into it; #37 of 63 by trust here, #5 by citations
• Pulmonary and Respiratory Medicine — 58 citations into it; #584 of 770 by trust here, #129 by citations
• Hematology — 56 citations into it
• Surgery — 52 citations into it; #1,040 of 1,106 by trust here, #171 by citations

Whom Christopher Corless trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

1. M. Heinrich
2. M. Miettinen
3. Heikki Joensuu
4. D. Tuveson
5. J. Lasota
6. Brian J. Druker

Who trusts Christopher Corless overall

1. M. Heinrich
2. Heikki Joensuu
3. M. Miettinen
4. T. Yuan

Papers from Christopher Corless's perspective

Ordered by how strongly the researchers Christopher Corless trusts endorse each paper. Same corpus, a different order for every researcher.

1. Diagnosis of gastrointestinal stromal tumors: A consensus approach. (Human Pathology)
2. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. (New England Journal of Medicine)
3. Clinical management of gastrointestinal stromal tumors: before and after STI-571. (Human Pathology)
4. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. (Journal of Clinical Oncology)
5. Structural Basis for the Autoinhibition and STI-571 Inhibition of c-Kit Tyrosine Kinase* (Journal of Biological Chemistry)
6. Denaturing high‐performance liquid chromatography: A review (Human Mutation)
7. KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. (Cancer Research)
8. Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. (Blood)
9. Nonparametric Estimation from Incomplete Observations
10. Genes expressed in human tumor endothelium. (Science)

Their papers

• Guidelines for Validation of Next-Generation Sequencing–Based Oncology Panels (2017) — 658 citations
• Gastrointestinal stromal tumour. (2013) — 809 citations
• Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification. (2011) — 666 citations
• Gastrointestinal stromal tumours: origin and molecular oncology (2011) — 852 citations
• Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205. (2010) — 604 citations
• KIT Gene Mutations and Copy Number in Melanoma Subtypes (2008) — 640 citations
• Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor. (2008) — 728 citations
• Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. (2008) — 988 citations
• NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)--update of the NCCN clinical practice guidelines. (2007) — 660 citations
• Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. (2006) — 805 citations
• PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib. (2005) — 865 citations
• Consensus meeting for the management of gastrointestinal stromal tumors. Report of the GIST Consensus Conference of 20-21 March 2004, under the auspices of ESMO. (2005) — 775 citations
• Biology of gastrointestinal stromal tumors. (2004) — 1,198 citations
• The novel marker, DOG1, is expressed ubiquitously in gastrointestinal stromal tumors irrespective of KIT or PDGFRA mutation status. (2004) — 656 citations
• PDGFRA Activating Mutations in Gastrointestinal Stromal Tumors (2003) — 2,423 citations
• Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. (2003) — 2,287 citations
• Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies. (2002) — 672 citations
• Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. (2002) — 4,306 citations
• Diagnosis of gastrointestinal stromal tumors: A consensus approach. (2002) — 3,676 citations